BCDA · XBRL financial data

BioCardia financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BCDA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q1 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,872	1,156*	1,241	800	931	1,415*	1,530	1,368	936	1,128*	1,235	893
Selling, general and administrative	1,083	941*	1,089	852	825	906*	1,196	683	552	885*	1,031	730
Operating income (loss)	(2,598)	(2,084)*	(2,275)	(1,649)	(1,756)	(2,321)*	(2,726)	(2,051)	(1,488)	(2,013)*	(2,266)	(1,623)
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(2,574)	(2,072)*	(2,267)	(1,646)	(1,737)	(2,296)*	(2,712)	(2,049)	(1,483)	(1,984)*	(2,259)	(1,613)
Earnings per share, basic USD per share	(0.12)	—	(0.09)	(0.88)	(0.61)	—	(0.59)	(0.40)	(0.24)	—	(0.21)	(0.13)
Earnings per share, diluted USD per share	—	—	—	—	—	—	(0.59)	(0.40)	—	—	(0.21)	—
Weighted average shares, basic thousands of shares	21,616	—	25,133	1,877	2,827	—	4,636	5,060	6,278	—	10,812	12,093
Weighted average shares, diluted thousands of shares	—	—	—	—	—	—	4,636	5,060	—	—	10,812	—

† Share count changed about 1/13 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (BCDA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q1 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,835	1,103	949	1,421	4,930	2,371	949	980	5,287	2,496	951	4,117
Accounts receivable	104	63	58	10	10	0	—	10	—	20	20	30
Prepaid and other current assets	177	295	252	142	116	251	224	209	78	216	169	151
Total current assets	2,116	1,461	1,259	1,573	5,056	2,622	1,173	1,199	5,365	2,732	1,140	4,298
Property and equipment, net	114	94	75	61	47	33	21	17	13	16	16	13
Right-of-use asset	1,346	1,261	1,174	1,085	993	898	801	702	599	494	385	273
Total assets	3,747	2,987	2,679	2,890	6,267	3,724	2,166	2,089	6,148	3,413	1,712	4,755
Accounts payable	507	890	1,030	1,447	569	385	818	1,233	1,080	641	820	541
Accrued liabilities	36	75	116	4	28	22	243	41	108	34	52	30
Total current liabilities	3,330	3,608	4,071	4,071	2,840	2,321	3,234	3,642	3,310	2,432	2,778	2,055
Lease liability, non-current	1,077	982	883	780	674	566	452	333	211	86	0	0
Total liabilities	4,407	4,590	4,954	4,851	3,514	2,887	3,686	3,975	3,521	2,518	2,778	2,055
Accumulated deficit	(150,103)	(152,175)	(154,442)	(156,088)	(157,825)	(160,121)	(162,833)	(164,882)	(166,365)	(168,349)	(170,608)	(172,221)
Total stockholders' equity	(660)	(1,603)	(2,275)	(1,961)	2,753	837	(1,520)	(1,886)	2,627	895	(1,066)	2,700
Total liabilities and equity	3,747	2,987	2,679	2,890	6,267	3,724	2,166	2,089	6,148	3,413	1,712	4,755
Common shares outstanding (cover page) thousands of shares	21,619	20,219	27,304	2,124	4,584	4,680	5,178	5,801	10,613	10,940	11,375	15,139

† Share count changed about 1/13 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (BCDA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q1 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,574)	(2,072)*	(2,267)	(1,646)	(1,737)	(2,296)*	(2,712)	(2,049)	(1,483)	(1,984)*	(2,259)	(1,613)
Stock-based compensation	251*	184*	204	184*	177*	176*	170	98*	77*	85*	113	109*
Depreciation and amortization	21*	20*	19	17*	16*	15*	12	5*	4*	3*	3	3*
Net cash from operating activities	(2,412)*	(1,851)*	(1,530)	(1,312)*	(2,611)*	(2,573)*	(1,618)	(1,649)*	(1,672)*	(2,497)*	(1,659)	(1,735)*
Purchases of property and equipment	0*	0*	0	3*	2*	1*	0	1*	0*	6*	3	0*
Net cash from investing activities	0*	0*	0	(3)*	(2)*	(1)*	0	(1)*	0*	(6)*	(3)	0*
Proceeds from issuing common stock	92*	1,346*	1,466	1,849*	7,198*	39*	212	1,695*	6,783*	0*	225	5,084*
Net cash from financing activities	(58)*	1,119*	1,376	1,787*	6,122*	15*	196	1,681*	5,979*	(288)*	117	4,901*
Net change in cash	(2,470)*	(732)*	(154)	472*	3,509*	(2,559)*	(1,422)	31*	4,307*	(2,791)*	(1,545)	3,166*

† Share count changed about 1/13 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.